The rest of the Novo Nordisk portfolio Beyond semaglutide, Novo Nordisk markets two liraglutide products: Victoza (approved for type 2 diabetes in 2010, gaining a cardiovascular indication in 2017) and Saxenda (liraglutide 3 mg, approved for chronic weight management in 2014)
And though more than 40% of Americans under 65 with private insurance are likely eligible for GLP-1 medications, only about 12% of adults are currently taking one
The peptide safety and risks article covers the full spectrum of safety considerations, from sterile technique to recognizing adverse reactions
A slight weight increase of 1 to 3 pounds between weeks is also normal, especially around dose increases, during the first few days of a new exercise routine, or during menstrual cycles
Some employers expressed hope that life-style coaching would allow employees to have an off ramp and stop using GLP-1 drugs after some period of time